Navigation Links
Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session

SAN CARLOS, Calif., March 19, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that clinical data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase 2 trial looking at recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) will be presented in a V-poster presentation at the of Cardiology (ACC) 56th Annual Scientific Session taking place in New Orleans, LA, March 24-27, 2007.

    The presentation details are as follows:


    Date/Time: Monday, March 26, 2007, 12:00 - 1:00 p.m. CDT


    Presentation Number: 1202-252


    Abstract Title: Safety and Tolerability of a Novel Tissue Factor/Factor

    VIIa Inhibitor rNAPc2 in Patients With Non-ST-Elevation Acute Coronary

    Syndrome Managed Invasively: Results From the ANTHEM/TIMI 32 Trial


    About V-Posters: V-posters are narrated by a prerecorded expert commentary

    and can be accessed by cell phone as attendees view the poster. The

    posters will remain on display for the entire length of the meeting.


    About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential
'"/>




Page: 1 2 3

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:6/18/2013)... Conn. , June 18, 2013  It ... clients of Alliance Seating and Mobility, a subsidiary ... to access timely repair. This appears to be ... dramatic reduction of field service employees.  ... a great many of these clients are complex ...
(Date:6/18/2013)... LEANDRO, Calif. , June 18, 2013  Cataracts ...  According to the American Association of Ophthalmology, aging is ... a clouding of the eye,s natural lens. 22 million ... 2020, as Baby Boomers continue to age, that number ... high tech world of iPhones, iPads, smart-phones and computers, ...
(Date:6/18/2013)... Mass. , June 18, 2013  Decision ... advisory firms for pharmaceutical and healthcare issues, announces ... coverage of the Middle East ... Access Tracker analyzes the challenges and opportunities to ... four international regions comprising 24 countries. The countries ...
Breaking Medicine Technology:New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3
... , SEOUL, South Korea, Nov. 17 ... Securities Dealers Association Quotation System ("Arigene") (KOSDAQ: 067850), today announced ... announced merger agreement dated October 2, 2009 with Trimeris, Inc. ... of the expiration date of the tender offer being conducted ...
... , MARCY L,ETOILE, France, Nov. 17 bioMerieux ... test to help clinicians select the most appropriate treatment for ... emerging biomarkers, will be intended for use in both adjuvant ... 500,000 new cases of breast cancer are diagnosed each year ...
Cached Medicine Technology:Arigene Co., Ltd. Enters Into Amendment To Merger Agreement With Trimeris, Inc. 2Arigene Co., Ltd. Enters Into Amendment To Merger Agreement With Trimeris, Inc. 3Arigene Co., Ltd. Enters Into Amendment To Merger Agreement With Trimeris, Inc. 4bioMerieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment 2bioMerieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment 3
(Date:6/19/2013)... 2013 Indosoft Inc., developers of ... for Asterisk, announced today the availability of its ... offers improved options for extracting, consolidating and presenting ... contact center management. , Large Asterisk based contact ... it happens from the call center software. This ...
(Date:6/19/2013)... CoachingWebsites, the leading ... today its affiliation with Active Intelligence. ... websites and marketing solutions and capitalize on affiliate ... with Active Intelligence shows our overall dedication to ... says Greer Van Dyck, Online Marketing Expert at ...
(Date:6/19/2013)... 19, 2013 The Mesothelioma Victims ... Control of the 2500 to 3000 citizens, who will ... mesothelioma this year, about one third will be US ... diagnosed with this asbestos exposure form of cancer, or ... access to the nations most skilled mesothelioma compensation settlement ...
(Date:6/19/2013)... Francisco, CA (PRWEB) June 19, 2013 ... accelerating throughout 2013 across all industries as cash rich ... Despite the differences across industries, all M&A transactions have ... rigorous due diligence to verify the history and quality ... carefully considered. , But when due diligence involves ...
(Date:6/18/2013)... oBand Surgery Centers, a reputed name ... weight loss seminars in Los Angeles this month. Scheduled ... at their official website. oBand Surgery Centers are an ... highly skilled panel of surgeons and dedicated staff has ... senior executive working with oBand Surgery Centers said, “We ...
Breaking Medicine News(10 mins):Health News:Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity 2Health News:CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2
... lowering LDL cholesterol (“bad” cholesterol) to below 100 milligrams ... cholesterol-lowering drug is safe and results in fewer cardiovascular ... They initially took 10 milligrams of atorvastatin (Lipitor) a ... milligrams per deciliter a day or lower. Then, half ...
... A study conducted in Spain has focused on the ... which might be associated with an increased risk of ... during pregnancy has been proven to have disastrous effects ... period, and obstetric complications such as extra uterine pregnancy, ...
... gradually increased recommendations for daily calcium intake, largely from ... to promote healthy bones and prevent osteoporosis. But a ... of milk or other dairy products was not necessarily ... of at least 400 milligrams per day. ,Other ...
... also hide within the body for long periods of time, ... resistance is lowered. The latent infections thus pose repeated problems ... study researchers say a compound found in licorice is showing ... virus that lingers in the body. For the study researchers ...
... suffering from the bone-thinning disease osteoporosis may also be ... condition in which people have a difficult time digesting ... improve bone mineral density, or BMD, among patients with ... have thinning bones, but little study exists to suggest ...
... new way to boost stem cell research that will help ... a new way of growing human embryonic stem cells in ... potential to play an important role in regeneration of cells ... these are exposed to live animal cells and serum and ...
Cached Medicine News:
PDA application containing all 7,000+ Physicians' Current Procedural Terminology codes developed by the American Medical Association....
More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003....
Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
... BD Safety Knife with BD Xstar Blade ... that protects the blade in prodedure and ... based on a grind-less process for manufacturing ... outstanding sharpness and consistency. The arch ...
Medicine Products: